Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old: Week 48 and Final Analysis of Cohort 2 From the Open-label, Phase 2 PAINT Study
At week 48, rilpivirine achieved adequate viral suppression in antiretroviral-naïve children ≥6 to <12 years of age. The pharmacokinetic, safety and virologic profile of rilpivirine in this age group was consistent with observations in adults and adolescents living with HIV-1.
Authors
- Simon Vanveggel
- Francis Ssali
- Minaka Shibuya
- Ken Kurosawa (ORCID: https://orcid.org/0000-0003-3496-883X)
- Johan Lombaard (ORCID: https://orcid.org/0000-0002-3229-7182)
- Sandy Van Hemelryck (ORCID: https://orcid.org/0000-0002-0103-8225)
- Eva Natukunda (ORCID: https://orcid.org/0000-0002-2944-5412)
- Erika Van Landuyt
- Rodica Van Solingen‐Ristea (ORCID: https://orcid.org/0000-0003-2301-7430)
- Veerle Van Eygen (ORCID: https://orcid.org/0000-0001-8804-1613)
- Visal Moolasart (ORCID: https://orcid.org/0000-0002-1151-4790)
- Joseph Lutaakome
- Sharne Foulkes
Institutions
- Ministry of Public Health (TH)
- Johnson Controls (Japan) (JP)
- Bamrasnaradura Infectious Diseases Institute (TH)
- Joint Clinical Research Centre (UG)
- Uganda Virus Research Institute (UG)
Publication Details
- Journal
- The Pediatric Infectious Disease Journal
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1097/inf.0000000000004828
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Johnson and Johnson